{"name":"Taisho Pharmaceutical Co., Ltd.","slug":"taisho-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"taisho-holdings.co.jp","description":"Taisho Pharmaceutical Co., Ltd. , commonly known as Taisho, is a Japanese multinational pharmaceutical company based in Tokyo.","hq":"Tokyo","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Loqoa","genericName":"ESFLURBIPROFEN","slug":"esflurbiprofen","indication":"Osteoarthritis","status":"marketed"},{"name":"Nanozora","genericName":"OZORALIZUMAB","slug":"ozoralizumab","indication":"Rheumatoid arthritis","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Diclofenac diethylamine","genericName":"Diclofenac diethylamine","slug":"diclofenac-diethylamine","indication":"Acute pain and inflammation","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Placebo to TS-142","genericName":"Placebo to TS-142","slug":"placebo-to-ts-142","indication":"Phase 3 clinical trials for TS-142 are ongoing, but specific indications are not publicly available.","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"TS-152","genericName":"TS-152","slug":"ts-152","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"TS-172","genericName":"TS-172","slug":"ts-172","indication":"Treatment-resistant depression","status":"phase_3"}]}],"pipeline":[{"name":"Loqoa","genericName":"ESFLURBIPROFEN","slug":"esflurbiprofen","phase":"marketed","mechanism":"Prostaglandin G/H synthase 2","indications":["Osteoarthritis"],"catalyst":""},{"name":"Diclofenac diethylamine","genericName":"Diclofenac diethylamine","slug":"diclofenac-diethylamine","phase":"phase_3","mechanism":"Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","indications":["Acute pain and inflammation","Musculoskeletal pain and inflammation","Postoperative pain"],"catalyst":""},{"name":"Nanozora","genericName":"OZORALIZUMAB","slug":"ozoralizumab","phase":"marketed","mechanism":"Tumor necrosis factor","indications":["Rheumatoid arthritis"],"catalyst":""},{"name":"Placebo to TS-142","genericName":"Placebo to TS-142","slug":"placebo-to-ts-142","phase":"phase_3","mechanism":"TS-142 is a drug with an unknown mechanism of action.","indications":["Phase 3 clinical trials for TS-142 are ongoing, but specific indications are not publicly available."],"catalyst":""},{"name":"TS-152","genericName":"TS-152","slug":"ts-152","phase":"phase_3","mechanism":"TS-152 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"TS-172","genericName":"TS-172","slug":"ts-172","phase":"phase_3","mechanism":"TS-172 is a small molecule that targets the serotonin receptor.","indications":["Treatment-resistant depression"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNY0paTlREYU1FOW4tOC1DNlFLM0tjaWQwcXVmSEpPN1ZoSndCTlU2eXhpUXRlbnpQMjM4OEZfbmNybWVIdFhaeTIwdTNxV21xay0zQVFUMzNMUnFMU2ZmcjQ1RVRsNEljUTJkdnJBTFZwMGVBNTdmOTU1b3hTcGZnbXo5MjYxNkxTeGJWT2FUNjBZQ1lHZkIycFZIekFEVXp3Szk2ZVdSNTAyYzUtVFVVWk9PNGQ3TGxHRjdDaFA5N21obUZDV3VIVks2QVMyOXhXdVJZMjFTVk1ZZkZwdXpNeEZNcGJJanlvTmM1TlVVT0ZaRG9wVXlrdDV3cFRsem9kOE1yeVFXdXFNdw?oc=5","date":"2026-03-30","type":"deal","source":"Business Wire","summary":"Biocytogen Grants Taisho Pharmaceutical a License to its RenNano - Business Wire","headline":"Biocytogen Grants Taisho Pharmaceutical a License to its RenNano","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNeWR4QkJHMnRoRXlnS0NJWkt2NFBCc1VRRUxWalBLWnBVYmJ6enNuWnpwYmJ4NURHdWlQamV6dWJmNTlmeUlYeER5Zmc5MVgxQVlOV25laEgwb1otSVFrUjZXU1o5bGFjZEc4cGdic0RNSUNHYkZWU0hfenp1Q3cwVmNVOElTRXYyY2hfMnZPUkFYbW9VelVaVE16Y3ZYNW5YVWstMnpYU0RCbGVic0ZFcFNTQ09nSUlvZVpxbV9NZVppaHdmUDlqd2l4eXdyZDJk?oc=5","date":"2026-03-30","type":"deal","source":"National Today","summary":"Biocytogen Grants Taisho Pharmaceutical License to RenNano® Antibody Platform - National Today","headline":"Biocytogen Grants Taisho Pharmaceutical License to RenNano® Antibody Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8wFBVV95cUxOWGJaVmlZVGJsRnRjWW1tQmxHTEUybXMxWnp1b1R3OXVwYmRpLWNoNjVYMFBTcUtfRFIzS0wxVVpSS3VLREE2S0UxclhoS2J1WlItNm5IN3hoZzI2SkdSNjZ6WmVrVkxmQnAwbTQ3YlZyV1VHZlZMb1hYYzdlcmowelV1S29RdE55U1J5ZVhIVnRGQ2tFWWhIVTQ0V3BYM0EwdURVT282QnBSM2FYRFE3NG1HYzNobjJhUGNGSmhGMmsyZVQ5R2NCSFpHSXkwcXJBTGdKazFIOGlVcHpzWURoQWZsWWRDZVIwR2xYV0x2c2hnY0U?oc=5","date":"2026-03-30","type":"pipeline","source":"Via TT","summary":"Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform - Via TT","headline":"Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNb3M0ek14cGtWaVBXdlNIbDR5a1p2NzdtQkFYR09zNm9xazVMZlY1MnpNcGo0YkhVNnNGbFlTaFZFQV90V25fal9MWkhxWmtMQm5RenpMLVNWN05MZUpIZTF4Z1BfOXluaHVlbXNUS3lZWUR6ek1yS01iWng0NXUtTEQ3YTR6bzFENGJKVHBOQmk3LVBDOWU1cDI2VjNVWXAwUWgtcS14azF4Z0JjQ2pCUWk0WUpobnRIaUZrNDBfdWhrc003eTE4YTJBZmtvN00?oc=5","date":"2026-02-10","type":"deal","source":"The Hearing Review","summary":"AudioCardio Partners with Taisho Pharmaceuticals to Launch Hearing App in Japan - The Hearing Review","headline":"AudioCardio Partners with Taisho Pharmaceuticals to Launch Hearing App in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOU3lsNjVRVXowSGdWZ0plSWhhWUZoWEd0VERldmlWNUNXZl9PMHlqenBnRE9ZR2VTZ1JvMUZFWjllb0NFTnl4LUhBRGxFOVFwTDgzWlBjcWg3VlFVQXhtZDRoZWVrZHVGSnFyN01KR1FJcW4xODlIZkFiWko2M01OSXRMcmhVSVN2b0J2ZmVZVEU1STV5N2dQbjNtdHlwSmdpUjhIQVlNZEM2SXpKVGdiWThuWlBPeUNYZ2RXMjJJVHhSdmVmRWI0ejZuTDl3OXpGbmg1N0UzZExwbjBEb0w4dA?oc=5","date":"2026-02-10","type":"pipeline","source":"Barchart.com","summary":"The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight - Barchart.com","headline":"The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOT1hTVnZreC1XUWg0Z29KdkdXazVHUmEwNFRoaG1KRHZaRFRoMzFIeUVDME5wSzRPV0EzTUMtX0N3NGljQVNmMy1lZEdfSHAwb0Ffd3dGQThwZHJmRnBXQTMtNVFrd1hNM2ZzMG0zY0FFdC1Yai0wal95MWxzVW5idHdKWGhBc01Td0NDN0Rsdm5sR1ZrZkQxMFNtWU1DWWNWVUswU2JlbFB4bURxb0Z6Yw?oc=5","date":"2026-01-07","type":"deal","source":"Bloomberg.com","summary":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal - Bloomberg.com","headline":"Buyout Wave Seen Among Japan Drugmakers After Hisamitsu Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9sUFVGQTlTaXJSeE54eTZsQk5rRnBONXNEeE1VQ0dkbmxEa2hjTEJLcUt1amtQdjVIR2xEOHl4YjA2SmdCbEJIU2VmazBLYlpuZUswN0Q2SnpfMTQ2S0k1cUotdllWaTBO?oc=5","date":"2025-10-09","type":"regulatory","source":"Wiley Online Library","summary":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal function: A randomized open-label clinical trial (RESOLUTION study) - Wiley Onli","headline":"Efficacy of luseogliflozin for renal function preservation in patients with type 2 diabetes mellitus and impaired renal ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQREZhSVVSWFk2VTVoNGpMZlJhNFQtdV9xd3E4MFNsNFVGT0h2NTJ0UXVKekNacTMxX1FXSGNUVDZMRnB4aGRoWFIxdnN3YmQzMHBjU2JNeURnbnRBS3VvbzdmQjhWZklVVXRZajVESVkwTjdVTUI5eE9QNmJwdmlpaktZdkFDWU1mRkpyenZ4OXpTUQ?oc=5","date":"2025-05-14","type":"pipeline","source":"Theinvestor","summary":"Vietnam's major pharma firm DHG to pay 60% cash dividend - Theinvestor","headline":"Vietnam's major pharma firm DHG to pay 60% cash dividend","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNY2czbEZialdPWUZRREpLTVNXVWNqR1p3ZVZCNTRvM2QzMVBWT2hrdzFscmd1UVUtRFZ6clZvSDJOTTZvcDZ5X2tMWnhGblBuckQ3MjZwUzZ0aHlUaWp6Sm4wUXV4VzBaZURYbm5wRy1qc0drQW5EeXdsYjF4NnBjWTVnMW0?oc=5","date":"2024-07-15","type":"deal","source":"pharmaphorum","summary":"Investors take issue with Taisho Pharma’s buyout price - pharmaphorum","headline":"Investors take issue with Taisho Pharma’s buyout price","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE1hODgxMWoxMm9WU0N1OXA0YmVON000MjdmNGRrWGE4N1MyaDNvblV4UDNuMmQ3Z1VvcTRJOHI4YTg3SjBSOURsOUJ0NXdDMWRYaXh0Q3lnYlFZblk?oc=5","date":"2020-10-15","type":"deal","source":"EurekAlert!","summary":"Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery - EurekAlert!","headline":"Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOQWZEU3pvNWJTTmk1dUxLZEdWakVUYkJ4dktyLTR4dzBJc0lfQnpNRUdtVC1JOU1fcVRfZGdSdDY2NllQWndKbjRHNFhsTTRqQkl4d0hxdlRCbFhXXzVzM3ZmSFEyOXk0dEk3VzQwNmF6bHVUVF9leVZwUkMwTHJRSFB5aUx4MXJFalE?oc=5","date":"2019-07-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Taisho Pharmaceutical concludes acquisition of BMS’ UPSA - Pharmaceutical Technology","headline":"Taisho Pharmaceutical concludes acquisition of BMS’ UPSA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxOdGphNm1uWVNEOU50SU0xX0JOeDZGQUpGWmp1d1p0bUJGNTRfVmFlSk9RejZMN3pJTXhHRzJpMGNmNENVbEJseWhGQ0xZZDhlUEtpVFdCZGh6RVluN0pzS09adEp5YmViYWtPRXFlRTEzZ19JWDV3WnRQUVFZX2Q3Q3FCeXhCOXB2V014QjhndkprY3NnUWhZQ3RHdzFLRG5Gc0xMMS1Gdm1hbGVPTkFjMDhvUmhWRTVMM1FISXhOTE9Ga0hDQ0twY3pfRmxpdFpQbFRyZGVqMXE1LW9GeFRFalNoU0s0ZHo5bVo1VTBzaDExODdlNDZoQTBJcklvcHNDbHk1Q1B5cHdZV1pRMW9zU0R3SQ?oc=5","date":"2019-04-16","type":"pipeline","source":"DC Advisory","summary":"DC Advisory advised Taisho Pharmaceutical on a dual stage acquisition of 51% stake in Duoc Hau Giang Pharmaceutical JSC - DC Advisory","headline":"DC Advisory advised Taisho Pharmaceutical on a dual stage acquisition of 51% stake in Duoc Hau Giang Pharmaceutical JSC","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":2,"phase_3":4},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}